COMPASS Pathways (CMPS) Competitors $4.66 +0.33 (+7.49%) As of 03:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMPS vs. ADPT, EVO, JANX, EWTX, ABCL, ANIP, ETNB, COGT, TVTX, and SRPTShould you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Adaptive Biotechnologies (ADPT), Evotec (EVO), Janux Therapeutics (JANX), Edgewise Therapeutics (EWTX), AbCellera Biologics (ABCL), ANI Pharmaceuticals (ANIP), 89BIO (ETNB), Cogent Biosciences (COGT), Travere Therapeutics (TVTX), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical products" industry. COMPASS Pathways vs. Its Competitors Adaptive Biotechnologies Evotec Janux Therapeutics Edgewise Therapeutics AbCellera Biologics ANI Pharmaceuticals 89BIO Cogent Biosciences Travere Therapeutics Sarepta Therapeutics Adaptive Biotechnologies (NASDAQ:ADPT) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability. Do insiders & institutionals have more ownership in ADPT or CMPS? 99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 46.2% of COMPASS Pathways shares are held by institutional investors. 6.4% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 3.9% of COMPASS Pathways shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is ADPT or CMPS more profitable? COMPASS Pathways has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -74.84%. Adaptive Biotechnologies' return on equity of -62.79% beat COMPASS Pathways' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-74.84% -62.79% -24.55% COMPASS Pathways N/A -87.89%-57.77% Do analysts rate ADPT or CMPS? Adaptive Biotechnologies currently has a consensus target price of $11.33, indicating a potential upside of 4.36%. COMPASS Pathways has a consensus target price of $16.29, indicating a potential upside of 249.10%. Given COMPASS Pathways' stronger consensus rating and higher probable upside, analysts plainly believe COMPASS Pathways is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83COMPASS Pathways 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Which has more risk & volatility, ADPT or CMPS? Adaptive Biotechnologies has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Comparatively, COMPASS Pathways has a beta of 2.16, meaning that its share price is 116% more volatile than the S&P 500. Does the media prefer ADPT or CMPS? In the previous week, COMPASS Pathways had 12 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 13 mentions for COMPASS Pathways and 1 mentions for Adaptive Biotechnologies. COMPASS Pathways' average media sentiment score of 0.21 beat Adaptive Biotechnologies' score of 0.00 indicating that COMPASS Pathways is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral COMPASS Pathways 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, ADPT or CMPS? COMPASS Pathways has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$189.53M8.70-$159.49M-$0.96-11.31COMPASS PathwaysN/AN/A-$155.12M-$1.84-2.54 SummaryCOMPASS Pathways beats Adaptive Biotechnologies on 9 of the 15 factors compared between the two stocks. Get COMPASS Pathways News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMPS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPS vs. The Competition Export to ExcelMetricCOMPASS PathwaysMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$434.60M$7.08B$5.57B$9.50BDividend YieldN/A2.90%4.74%4.13%P/E Ratio-2.5265.5229.1324.33Price / SalesN/A34.08435.22175.21Price / CashN/A25.5124.4827.20Price / Book2.068.058.535.75Net Income-$155.12M$239.96M$3.24B$264.99M7 Day Performance7.49%2.44%-1.22%-2.38%1 Month Performance43.14%1.26%7.58%6.75%1 Year Performance-33.74%22.13%26.92%20.38% COMPASS Pathways Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPSCOMPASS Pathways2.7959 of 5 stars$4.67+7.5%$16.29+249.1%-38.4%$434.60MN/A-2.52120News CoverageEarnings ReportAnalyst ForecastADPTAdaptive Biotechnologies2.4423 of 5 stars$10.61-1.3%$10.57-0.4%+140.2%$1.61B$189.53M-11.05790Upcoming EarningsEVOEvotec2.1014 of 5 stars$4.26flat$5.93+39.3%-9.0%$1.51B$862.40M0.004,827Gap DownJANXJanux Therapeutics2.8754 of 5 stars$25.55-1.6%$91.89+259.6%-39.2%$1.51B$10.59M-18.7930Positive NewsUpcoming EarningsEWTXEdgewise Therapeutics2.2126 of 5 stars$14.26+1.0%$40.00+180.5%-11.9%$1.50BN/A-9.2060Upcoming EarningsABCLAbCellera Biologics2.5931 of 5 stars$4.92-3.7%$8.75+77.8%+45.2%$1.47B$28.83M-8.79500Upcoming EarningsANIPANI Pharmaceuticals3.6849 of 5 stars$66.50-1.5%$78.88+18.6%+4.8%$1.44B$614.38M-52.36600Upcoming EarningsETNB89BIO2.3484 of 5 stars$9.53-0.6%$26.43+177.3%+2.8%$1.39BN/A-2.8240COGTCogent Biosciences3.0605 of 5 stars$12.09+0.2%$18.70+54.7%+21.3%$1.38BN/A-6.5780Upcoming EarningsTVTXTravere Therapeutics1.9078 of 5 stars$15.40+0.5%$32.14+108.7%+73.7%$1.37B$233.18M-5.48460Upcoming EarningsShort Interest ↑SRPTSarepta Therapeutics4.605 of 5 stars$13.86+16.2%$51.42+271.0%-88.9%$1.36B$1.90B-5.151,372Upcoming EarningsHigh Trading Volume Related Companies and Tools Related Companies ADPT Competitors EVO Competitors JANX Competitors EWTX Competitors ABCL Competitors ANIP Competitors ETNB Competitors COGT Competitors TVTX Competitors SRPT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMPS) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding COMPASS Pathways PLC Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share COMPASS Pathways With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
